Anti-Lp-PLA2 Antibody (Rabbit Polyclonal antibody) General Information
Reacts with: Human
Recombinant Human PLA2G7 / PAFAH protein (Catalog#10848-H08H)
Produced in rabbits immunized with purified, recombinant Human PLA2G7 / PAFAH (rh PLA2G7 / PAFAH; Catalog#10848-H08H; Q13093-1; Met 1-Asn 441). Total IgG was purified by Protein A affinity chromatography.
Polyclonal Rabbit IgG
0.2 μm filtered solution in PBS with 5% trehalose
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Anti-Lp-PLA2 Antibody (Rabbit Polyclonal antibody) Validated Applications
**********Please Note: Optimal concentrations/dilutions should be determined by the end user.**********
Anti-Lp-PLA2 Antibody Alternative Names
Anti-LDL-PLA2 Antibody;Anti-LP-PLA2 Antibody;Anti-PAFAD Antibody;Anti-PAFAH Antibody
Lp-PLA2 Background Information
Platelet-activating factor acetylhydrolase, also known as 1-alkyl-2-acetylglycerophosphocholine esterase, 2-acetyl-1-alkylglycero-phosphocholine esterase, Group-VIIA phospholipase A2, LDL-associated phospholipase A2, PAF 2-acylhydrolase, PLA2G7 and PAFAH, is secreted protein which belongs to the AB hydrolase superfamily and Lipase family. PLA2G7 / PAFAH modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. It has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids. PLA2G7 / PAFAH is a potent pro- and anti-inflammatory molecule that has been implicated in multiple inflammatory disease processes, including cardiovascular disease. PLA2G7 also represents an important, potentially functional candidate in the pathophysiology of coronary artery disease (CAD). Defects in PLA2G7 are the cause of platelet-activating factor acetylhydrolase deficiency (PLA2G7 deficiency). It is a trait which is present in 27% of Japanese. It could have a significant physiologic effect in the presence of inflammatory bodily responses.
phospholipase A2 group VII
Stafforini D.M., et al., 1996, J. Clin. Invest. 97:2784-2791. Yoshida H., et al., 1998, Thromb. Haemost. 80:372-375. Yamada Y., et al., 1998, Metabolism 47:177-181. Kruse S., et al., 2000, Am. J. Hum. Genet. 66:1522-1530.